Lipiodol was discovered for the use of radiology, till date this injection is a prescription oil-based radio-opaque contrast agent indicated for cTACE, diagnosis liver lesions, vascular embolisation with medical cyanoacrylate glues, lymphography and endocrinology in adult as well as pediatric patients
Guerbet, a medical imaging company, hosted its first India virtual media roundtable, titled ‘Guerbet in India and 100 Years & Beyond of Lipiodol’.
In 1921, Lipiodol® (ethiodised oil) was discovered for the use of radiology, till date this injection is a prescription oil-based radio-opaque contrast agent indicated for conventional trans-arterial chemo-embolisation (cTACE), diagnosis liver lesions, vascular embolisation with medical cyanoacrylate glues, lymphography and endocrinology in adult as well as pediatric patients.
In attendance were Dr Sanjay Saran Baijal, Chairman of Diagnostics & Interventional Radiology at the Medanta – The Medicity; Dr Vimal Someshwar, Head of Department, Intervention & Diagnostic Radiology, at the Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Ghosh TP, General Manager, India at Guerbet and Mathieu Elie, Chief Commercial Officer (CCO), Asia Pacific at Guerbet. The panellists discussed Lipiodol’s effect on disease management across India and beyond, and its use and future application in the country.
Both Dr Someshwar and Dr Baijal gave presentations relating to the use of Lipiodol in disease management. Dr Baijal presented on ‘Lipiodol – Management of Hepatocellular Carcinoma (HCC) & as the Foundation for Lymphatic Interventions’, while Dr Someshwar gave an overview of his ‘Lipiodol: Comprehensive Indications’ research and work.
- Advertisement -